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“[In order] to improve pediatric bone health, which has lifelong implications, a 
correct evaluation of the etiology and pathogenesis of diseases, and the role of 
diseases and/or treatments on bone health, are mandatory.”
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Managing pediatric osteoporosis
Pediatric osteoporosis (PO) is a condition that 
is increasingly recognized, rarely due to pri-
mary genetic diseases of the bone, but more fre-
quently a consequence of chronic illness and/or 
treatments [1,2]. 
Considering dual-energy x-ray absorptio-
metry as the gold standard to evaluate bone 
status, the relationship between bone mineral 
density (BMD) and risk of fracture in children 
is unknown; therefore, it is not possible to define 
thresholds below which there is an established 
increased risk. Furthermore, BMD measure-
ments in children are affected by body size as 
the bone density value produced is an areal bone 
density (aBMD), failing to provide a volumetric 
BMD (vBMD). So, a child who is short for their 
age may receive an inappropriate diagnosis of 
osteoporosis [3]. Normal BMD values now exist 
for children aged 7 years and older [4], and there 
is also a position statement on bone densitom-
etry in children, which states that PO diagnosis 
should be made on the basis of a low BMD or 
bone mineral content (z-score ≤-2.0, adjusted for 
age, gender and body size), and the presence of a 
clinically significant fracture history [5]. 
Causes of pediatric osteoporosis
Genetic factors play an essential role in the patho-
genesis of PO. Many genes have been discovered 
as possible candidates for the regulation of bone 
mass [6]; however, the mechanisms that underlie 
the association between given genes and osteo-
porosis are poorly understood [1,2]. An essential 
point for improving bone health is to reach a 
high peak bone mass (PBM). Even if the main 
factor for achieving a normal PBM in healthy 
individuals is genetically determined [6], PBM 
may be a major determinant of bone mass later in 
life [6,7], and it is critical to maximize the poten-
tial of reaching the most optimal value through 
management of potential factors contributing to 
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bone loss and osteoporosis. Environmental fac-
tors (e.g., sex hormones, calcium and vitamin 
D dietary intake, medication use and sedentary 
lifestyle) account for approximately 25% of the 
variance in PBM [6]. Furthermore, while PBM 
is typically attained by 30 years of age, approx-
imately 90% of PBM is reached by the age of 
18 years in females and 20 years in males [8]. 
The greatest loss of bone and mineral occurs 
due to genetic defects, such as osteogenesis 
imperfecta (OI) and X-linked hypophospha-
temic rickets (XLH), but enzymatic defects 
such as hypophosphatasia and homocystinuria, 
and disorders of copper transport, such as Wil-
son’s disease and Menkes’ kinky hair syndrome, 
are also conditions that can lead to severe bone 
demineralization. Other rare causes of PO include 
idiopathic juvenile osteoporosis (IJO) [1,2], the 
osteoporosis–pseudoglioma syndrome, and the 
juvenile and early-onset Paget’s disease [9].
Secondary causes of PO are much more com-
mon in children [1,2]. Secondary osteoporosis is 
typically multifactorial and it occurs as a con-
sequence of systemic inflammatory diseases, 
which affect bone metabolism and endocri-
nopathies that act via altered hormone levels 
[2]. Furthermore, other diseases, such as various 
eating disorders, GI tract diseases determining 
malabsorption, or hepatobiliary diseases, may 
cause a reduction of bone density and quality. 
Finally, any cause of prolonged immobilization, 
such as cerebral palsy (through a reduction of 
mechanical stress on bone), inhibits osteo-
blast-mediated bone formation and accelerates 
osteoclast-mediated bone resorption, leading to 
a decreased BMD. Neoplastic disorders (espe-
cially leukemia and lymphoma, but also many 
solid tumours) and medications (glucocorti-
coids [GCs], anticonvulsants, aromatase inhib-
itors, lithium and heparin) are also important. 
Finally, decreased dietary intake of calcium or part of
For reprint orders, please contact: reprints@futuremedicine.com
Int. J. Clin. Rheumatol. (2013) 8(5)510 future science group
Editorial Cimaz & Stagi
vitamin D deficiency may be additional risk 
factors for PO [1,2].
In the case of inflammatory disorders, IL-1b 
and IL-6 stimulate the osteoblast to produce 
RANKL, stimulating bone marrow stem cells 
to differentiate into osteoclasts, hence increasing 
bone resorption [9]. 
“Secondary osteoporosis is typically 
multifactorial and it occurs as a consequence 
of systemic inflammatory diseases, which 
affect bone metabolism and endocrinopathies 
that act via altered hormone levels.”
With regard to pediatric rheumatic diseases, 
much data incontrovertibly showed that juvenile-
onset systemic lupus erythematosus patients are 
more prone to suffer from decreased BMD [1,7, 10], 
with a prevalence of osteopenia and PO of 37.5 
and 20.3%, respectively [10]. Multiple causes, 
involving both disease- and nondisease-related 
factors, have been proposed as main reasons for 
bone loss, including reduced physical activity, 
limited exposure to sunlight, systemic inflamma-
tion, GCs, delay in pubertal development, inade-
quate dietary intake of calcium and vitamins, use 
of cytotoxic drugs and disease severity, especially 
nephritis. Similar findings have been reported for 
dermatomyositis, even if, in this condition, the 
relatively reduced  mobilization in myositis may 
also play a role [1,2]. 
Children and young adults with juvenile idio-
pathic arthritis showed a decreased BMD [1,7], 
particularly in polyarticular and systemic groups 
[7], with a reduced PBM and an increased risk 
of developing adult osteoporosis [1,2, 7]. Disease 
severity, inflammatory mediators and GCs have 
a definitive pathogenetic role for low BMD and 
reduced PBM [1,7]. 
Management of pediatric 
osteoporosis
Since the cause of bone loss is frequently mul-
tifactorial and the exact pathogenic mechanism 
of PO has not been clearly established in many 
conditions, it is difficult to proceed with rational 
treatments and prevention. For example, nutri-
tional supplements in malabsorption or appro-
priate antibiotic therapy in cystic fibrosis may be 
useful in the management of bone loss in children 
and young adults with these conditions. At the 
same time, dietary interventions can improve 
bone health [11], and physical activity and exercise 
during childhood have been identified as primary 
methods of preventing PO and enhancing skeletal 
development [12]. 
Therefore, it is evident that a multidisciplinary 
approach will often be required for the correct 
management of PO. In addition to a pediatrician 
and a pediatric rheumatologist or endocrin ologist, 
familiar with OP management, an important 
part of this team are radiologists, who should be 
experienced in undertaking bone density scans 
in children. Other healthcare professionals, such 
as physiotherapists and occupational therapists, 
orthopedic surgeons and specialist nurses also 
play a role. 
To begin with, we must ask what therapies 
are currently available to treat or prevent bone 
loss in children. The number of drugs to treat 
bone fragility in children is limited and most 
have never been established as safe or effective 
in randomized controlled trials. 
Furthermore, while in adults the guidelines for 
the treatment of osteoporosis are widely accepted, 
limited data for children and adolescents with 
PO makes it harder to set clear guidelines for 
the pediatric population. Moreover, there are 
few guidelines on how to use bone-active drugs 
in children and a consensus is needed among 
pediatric caregivers as to what conditions would 
most benefit from which drug [1].
With regard to genetic diseases, few specific 
treatments are available, short of gene therapy 
or stem cell transplantation. Exceptions to this 
appear to be the use of intravenous bisphos-
phonates in OI [2] or the use of phosphate and 
1,25-dihydroxyvitamin D in XLH [2]. 
For conditions in which bone resorption is the 
primary defect, treatment with an antiresorp-
tive agent would be the most appropriate option; 
however, for conditions in which lack of new 
bone formation is the predominant finding, use 
of anabolic agents should be considered along 
with appropriate management of the underlying 
condition.
“...it is evident that a multidisciplinary 
approach will often be required for the 
correct management of pediatric 
osteoporosis.”
Vitamin D and calcium are important for 
maintaining adequate bone homeostasis and 
facilitating bone remodeling and growth. Even 
if in the presence of vitamin D deficiency and/or 
poor dietary calcium intake it is appropriate to 
replace such deficits, routine calcium and vita-
min D supplementation is not recommended. 
In a meta-ana lysis, a reduced change in BMD 
was showed after calcium supplementation in 
healthy children [13]. 
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In recent years, reduced sun exposure and 
a decrease in outdoor activities, in addition to 
an increased use of sunscreen and an increas-
ingly lower time devoted to physical activity, are 
among the causes of decreased vitamin D levels 
in the general population.
In a large group of pediatric patients with 
osteoporosis or osteopenia, decreased levels 
of 25-hydroxyvitamin D were detected [14]. 
Although no direct connection with fracture risk 
may be found, vitamin D supplementation in 
children with osteopenia and PO is advisable and 
may indeed reduce morbidity. Low vitamin D 
levels, associated with decreased BMD levels and 
high parathyroid hormone levels, were found in 
juvenile idiopathic arthritis patients treated with 
GCs [1,2]. The recommended daily consumption 
of vitamin D may not be sufficient for patients 
undergoing bone-affecting treatments and for 
those suffering from primary bone disorders. 
Recent data strongly suggests that physical 
activity in childhood is one of the most pow-
erful preventive strategies against osteoporosis 
[12]. Weight-bearing physical activity during 
childhood and puberty affects bone mass and 
formation [12]. More and more data are available 
that support the importance of physical activ-
ity during childhood independently of exercise 
interventions for achieving optimal bone mass 
into young adulthood [12]. 
“In young subjects ... one standard deviation 
increase in peak bone mass would reduce 
fracture risk by as much as 50%.”
Many different physical activities, in particu-
lar those characterized by a considerable loading 
magnitude applied at a fast rate, have proven to 
exert the greatest osteogenic effect on the growing 
skeleton [12]. So, weight-bearing activities, such as 
jumping, appear to determine the greatest ben-
efits to bone mineralization and structure during 
development. In young subjects, significant skel-
etal benefits are shown when the exercise stimulus 
is delivered for a sufficient time, highlighting the 
critical role to acquire an early active lifestyle to 
promote life-long skeletal health [12]. For example, 
Bonjour and colleagues have quantified that one 
standard deviation increase in PBM would reduce 
fracture risk by as much as 50% [15]. 
Bisphosphonates are used as the principal 
treatment of bone fragility in genetic forms such 
as OI. Bisphosphonates have also been studied 
as a potential preventive measure in other dis-
eases; for example, children with cerebral palsy 
have a 89% increase in BMD compared with 9% 
in controls [1,2]. In children receiving treatment 
with GCs, BMD was shown to decrease, but this 
was not observed in those patients receiving alen-
dronate [1,2]. In children with connective tissue 
disease [1,2], safety and increased z-scores were 
shown during treatment with alendronate. How-
ever, for primary prevention, the use of bisphos-
phonates in children receiving corticosteroids for 
chronic disease is not yet  recommended [2]. 
“The recommended daily consumption of 
vitamin D may not be sufficient for patients 
undergoing bone-affecting treatments and 
for those suffering from primary bone 
disorders.”
The most effective anabolic agent in adults, 
recombinant human parathyroid hormone, is 
not approved for use in children. In fact, several 
concerns exist regarding its safety, especially in 
younger patients, because of the development of 
bone tumors, particularly osteogenic sarcoma in 
young rats [1,2,16]. However, recombinant human 
parathyroid hormone is given to hypopara-
thyroid children [16], although long-term follow-
up studies have not been carried out to assess the 
risk of osteogenic sarcoma in this population.
Conclusion
In summary, children may be affected by both 
primary and secondary bone loss. Primary bone 
loss involves genetic mutations leading to fun-
damental defects in either collagen synthesis 
or bone mineral conservation. Secondary bone 
loss results from the body’s response to a variety 
of acute and chronic conditions and/or treat-
ment. Since the goal is to improve pediatric 
bone health, which has lifelong implications, 
a correct evaluation of the etiology and patho-
genesis of diseases, and the role of diseases and/
or treatments on bone health, are mandatory. A 
healthy lifestyle, physical activity and nutritional 
supplementation, such as calcium and vitamin D 
(when necessary), are first-line treatments. 
New medications, such as biphosphonates, are 
recommended in severe cases.
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